Autopsy report · NCT02186821

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

“Study was terminated due to low enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 3 months before it stopped.
• 47 participants enrolled.
• Results were posted on the registry 3 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Tumors With Aberrations in ALK or ROS1

Interventions

Ceritinib

Participants

47

Sites

21

Countries

United States

Trials that died the same way

• A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
  “Study was terminated due to poor enrollment” (97% match in meaning)
• Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
  “Study terminated due to low enrollment.” (97% match in meaning)
• Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
  “The study was terminated due to low enrollment” (97% match in meaning)
• Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
  “The study is terminated due to lower enrollment” (95% match in meaning)
• Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
  “the study was terminated early due to poor enrollment” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.